Knights of Columbus Asset Advisors LLC Raises Stock Position in Insmed Incorporated (NASDAQ:INSM)

Knights of Columbus Asset Advisors LLC raised its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 101.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 228,783 shares of the biopharmaceutical company’s stock after buying an additional 114,987 shares during the quarter. Knights of Columbus Asset Advisors LLC owned about 0.16% of Insmed worth $7,090,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of INSM. International Assets Investment Management LLC acquired a new position in shares of Insmed during the 4th quarter valued at about $25,000. Almanack Investment Partners LLC. purchased a new position in shares of Insmed in the third quarter valued at approximately $25,000. State of Wyoming purchased a new position in shares of Insmed in the fourth quarter valued at approximately $31,000. Quantbot Technologies LP boosted its stake in shares of Insmed by 2,170.4% in the second quarter. Quantbot Technologies LP now owns 2,452 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 2,344 shares during the period. Finally, RVW Wealth LLC purchased a new position in shares of Insmed in the third quarter valued at approximately $53,000.

Analysts Set New Price Targets

INSM has been the topic of several analyst reports. UBS Group initiated coverage on shares of Insmed in a report on Tuesday, February 27th. They issued a “buy” rating and a $46.00 target price on the stock. Guggenheim raised their price objective on shares of Insmed from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Wells Fargo & Company reissued an “overweight” rating and set a $55.00 price objective on shares of Insmed in a report on Monday, April 1st. Wolfe Research initiated coverage on shares of Insmed in a research report on Thursday, February 15th. They issued an “outperform” rating and a $42.00 price objective on the stock. Finally, Barclays boosted their target price on shares of Insmed from $37.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 11th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.64.

Insmed Stock Down 2.6 %

INSM stock traded down $0.64 during trading on Friday, reaching $24.16. 1,371,560 shares of the company’s stock were exchanged, compared to its average volume of 1,688,090. Insmed Incorporated has a 1-year low of $17.41 and a 1-year high of $32.00. The company’s fifty day moving average price is $27.45 and its 200-day moving average price is $27.02. The firm has a market cap of $3.59 billion, a PE ratio of -4.64 and a beta of 0.92.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.13) by ($0.15). The company had revenue of $83.70 million during the quarter, compared to analysts’ expectations of $82.15 million. The company’s revenue for the quarter was up 41.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.20) earnings per share. As a group, sell-side analysts expect that Insmed Incorporated will post -4.65 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.